Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on LinkedIn:
“NEST Trial
Lessons: Independent data corroboration
The UNICORN trial reported on neoadjuvant BOT alone and BOT+BAL at American Society of Clinical Oncology (ASCO) GI25 conference, independently corroborating NEST while also addressing contribution of components.
The PD-1 partner matters.
OncoAlert
Here’s a link to the UNICORN study from GONO.”
Title: Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial Open Access
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
Title: Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO.
Authors: Filippo Ghelardi, Margherita Ambrosini, Alessandra Raimondi, Giovanna Sabella, Riccardo Cerantola, Federica Palermo, Samantha Di Donato, Daniele Spada, Stefano Tamberi, Eleonora Perissinotto, Francesca Bergamo, Alessandro Passardi, Emiliano Tamburini, Riccardo Rosati, Andrea Sartore-Bianchi, Marcello Guaglio, Chiara Cremolini, Isacco Montroni, Sara Lonardi, Filippo Pietrantonio
